| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary target of fibrin is not a receptor but rather the polymerization process itself. Fibrin interacts with various proteins and cells involved in hemostasis and wound healing, including platelets, thrombin, factor XIII, and plasminogen. It provides a scaffold for cell adhesion and migration, and it regulates the activity of various proteases and growth factors through binding interactions. The fibrin clot also serves as a temporary matrix for the deposition of extracellular matrix components during wound healing.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that fibrin forms a three-dimensional network when thrombin is added to fibrinogen. The polymerization process can be studied using turbidity measurements, which monitor the increase in absorbance as the fibrin clot forms. Fibrin binds to various proteins and cells, including platelets, fibroblasts, and endothelial cells. The degradation of fibrin by plasmin (fibrinolysis) can also be studied in vitro. These studies provide insights into the properties and functions of fibrin.
|
| ln Vivo |
In vivo, fibrin is essential for hemostasis and wound healing. After tissue injury, fibrinogen is converted to fibrin by thrombin, and the fibrin clot forms to stop bleeding. The clot then serves as a scaffold for cell infiltration and tissue repair. Fibrin is subsequently degraded by plasmin as part of the wound healing process. Abnormalities in fibrin formation or degradation can lead to bleeding disorders or thrombosis. Fibrin-based products are used clinically as hemostatic agents and tissue sealants.
|
| Enzyme Assay |
Non-cellular assays for fibrin typically involve studying its polymerization using turbidity or light scattering measurements. The clotting time of fibrinogen in the presence of thrombin is measured using coagulation assays. The binding of various proteins (e.g., plasminogen, fibronectin) to fibrin can be assessed using ELISA or surface plasmon resonance. The degradation of fibrin by plasmin can be studied by measuring the release of fibrin degradation products.
|
| Cell Assay |
Cellular assays for fibrin involve studying the interactions of cells with fibrin matrices. Platelet aggregation and adhesion to fibrin can be assessed using aggregation assays or adhesion assays. The migration of fibroblasts, endothelial cells, or other cell types on fibrin matrices can be studied using migration assays or wound healing assays. The effects of fibrin on cell proliferation and differentiation can be assessed using standard cell culture techniques.
|
| Animal Protocol |
In vivo animal experiments for fibrin are typically conducted to study hemostasis, wound healing, or thrombosis. Bleeding time assays and tail vein transection models are used to assess hemostatic function. Wound healing models are used to study the role of fibrin in tissue repair. Thrombosis models are used to study pathological fibrin formation. Fibrin-based products are tested in animal models to assess their efficacy and safety as hemostatic agents or tissue sealants.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of fibrin as a protein are not typically characterized in the same way as small molecule drugs. When used as a hemostatic agent, fibrin is applied locally and forms a clot that is subsequently degraded by the body's fibrinolytic system. The half-life of the fibrin clot depends on the balance between clot formation and degradation. When used as a biomaterial, the degradation rate of fibrin can be modulated by the incorporation of protease inhibitors or by crosslinking.
|
| Toxicity/Toxicokinetics |
Toxicological data for fibrin are limited, as it is a natural protein. When used as a hemostatic agent or tissue sealant, fibrin-based products are generally well-tolerated. Potential adverse effects include allergic reactions (rare) and the risk of transmission of infectious agents (minimized by viral inactivation procedures). Thrombosis can occur if fibrin formation is excessive. The safety of fibrin-based products is well-established in clinical use.
|
| References | |
| Additional Infomation |
Fibrin is a peptide. Fibrin is a protein derived from fibrinogen under the action of thrombin and is a component of blood clots.
Other information includes the use of fibrin as a biomaterial in tissue engineering and regenerative medicine. Fibrin scaffolds provide a biocompatible and biodegradable matrix for cell delivery and tissue repair. Fibrin-based products are used clinically as hemostatic agents, tissue sealants, and wound dressings. Fibrin glue is used to seal tissues and control bleeding in surgical procedures. Fibrin is also used in research to study cell-matrix interactions and wound healing. The protein is available from various suppliers for research and clinical applications. |
| Molecular Weight |
0
|
|---|---|
| Exact Mass |
145.085
|
| CAS # |
9001-31-4
|
| PubChem CID |
439199
|
| Appearance |
White to yellow solid powder
|
| Density |
1.146g/cm3
|
| Boiling Point |
471.7ºC at 760mmHg
|
| Flash Point |
239.1ºC
|
| Index of Refraction |
1.48
|
| LogP |
0.188
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
10
|
| Complexity |
135
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CNC(=O)CNC(=O)CN
|
| InChi Key |
BWGVNKXGVNDBDI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H11N3O2/c1-7-5(10)3-8-4(9)2-6/h2-3,6H2,1H3,(H,7,10)(H,8,9)
|
| Chemical Name |
2-amino-N-[2-(methylamino)-2-oxoethyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: < 0.1 mg/mL
DMSO: < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT01253135
Conditions:Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen SprayLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000025447
Condition:Early stage esophageal cancer after entire circumferential endoscopic submucosal dissection (ESD)Link: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000019619
Condition:Fistula of upper gastrointestinal tract
Title:Endoscopic closure of postsurgical esphageal fistula using polyglycolic acid sheets with fibrin glue
Status:Recruiting
Date:2015-11-04
Ctid:UMIN000019622
Link: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000019622
Condition:esophageal fistula due to esophagectomy for esophageal cancerLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000019027
Condition:Massive hemorrhage by trauma, gastrointestinal hemorrhageLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000016832
Condition:Early colon cancer,Colon adenomaLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000015091
Condition:early gastric cancer/gastric adenomaLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000013646
Condition:Retroperitoneal lymph node dissectionLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000011000
Condition:Intractable pneumothoraxLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000006430
Condition:Patients with intraocular fibrin formationProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
